Fig. 3From: (1,3)-β-d-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized triala (1,3)-β-d-Glucan results for patients with and without invasive Candida infections. b Duration of antifungal therapy among intensive care unit patients according to the absence or presence of invasive Candida infections and the positivity of the (1,3)-β-d-glucan assayBack to article page